Clinical study of Qiliqiangxin Capsules applied in elderly patients with heart failure complicated with decreased glomerular filtration rate
SUN Gui-feng1 LIU Yu2 WANG Yan-xia2 WANG Ying1 XUE Yu-zeng3▲
1.Department of Cardiology,Yanggu People′s Hospital in Shandong Province,Yanggu 252300,China
2.Department of Geriatrics,Yanggu People′s Hospital in Shandong Province,Yanggu 252300,China;
3.Department of Cardiology,Liaocheng People′s Hospital in Shandong Province,Liaocheng 252000,China
ObjectiveTo observe the safety and effectiveness of Qiliqiangxin Capsules applied in elderly patients with heart failure complicated with decreased glomerular filtration rate.MethodsA total of 172 elderly patients with heart failure complicated with decreased glomerular filtration rate treated in department of geriatrics were enrolled continuously from February to April 2016,and they were randomly divided into the two groups.The control group was treated with standardized treatment of heart failure,while the study group was treated with Qiliqiangxin Capsules on the basis of standardized treatment
received：.After 12 weeks,eGFR,B type natriuretic peptide (BNP)and Minnesota Living with Heart Failure questionnaire (MLHFQ)score were compared between the two groups.ResultsThere was no significant difference between the two groups before treatment(P＞0.05).After 12 weeks,the difference of BNP level and estimated eGFR and MLHFQ score in the two groups was statistically significant compared with before treatment(P＜0.05).Study group compared with the control group,the BNP level decreased[(865.0±124.5)pg/ml vs.(997.0±141.7)pg/ml(P＜0.05),the estimated eGFR improved[(74.2±16.2)ml/（min·1.73 m2） vs.(69.3±15.4)ml/（min·1.73 m2）](P＜0.05)and MLHFQ score decreased[(24.5±11.2)points vs.(36.6±12.3)points] (P＜0.05).ConclusionFor elderly patients with heart failure received Qiliqiangxin Capsules does not affect the renal function of patients based on standard treatment,and can improve cardiac function and improve the quality of life.
Djousse L，Driver JA，Gaziano JM.Relation between modifiable lifestyle factors and lifetime risk of heart failure[J].JAMA，2009，302（4）：394-400.
[4]
Roger VL，Weston SA，Redifield MM，et al.Trends in heart failure incidence and survival in a community-based population[J].JAMA，2004，292（3）：344-350
[5]
Levy D，Kenchaiah S，Larson MG，et al.Long-term trends in the incidence of and survival with heart failure[J].N Engl J Med，2002，347（18）：397-402.
[6]
Go AS，Mozaffarian D，Roger VL，et al.Heart disease and stroke statistics——2013 update：a report from the American Heart Association[J].Circulation，2013，127（1）：21-23.
[7]
Jong P，Yusuf S，Rousseau MF，et al.Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction：a follow-up study[J].Lancet，2003，361（9372）：1843-1848.
[8]
Lesman-Leegte I，Jaarsma T，Coyne JC，et al.Quality of life and depressive symptoms in the elderly：acomparison between patients with heart failure and age-and gender-matched community controls[J].J Card Fail，2009，15（1）：17-23.
[9]
Moser DK，Yamokoski L Sun JL，et al.Improvement in healthrelated quality of life after hospitalization predicts eventfree survival in patients with advanced heart failure[J].J Card Fail，2009，15（9）：763-769.
[10]
Rodriguez-Artalejo F，Guallar-Castillon P，Pascual CR，et al.Health-related quality of life as a predictor of hospital readmission and death among patients with heart failure[J].Arch Intern Med，2005，165（11）：1274-1279.
[11]
Majani G，Giardini A，Opasich C，et al.Effect of valsartan on quality of life when add to usual therapy for failure：results from the Valsartan Heart Failure Trial[J].J Card Fail，2005，11（4）：253-259.
[12]
Hunt SA，Abraham WT，Chin MH，et al.2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the Aerican College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation[J].J Am Coll Cardiol，2009，53（15）：e1-e90.
[13]
Yancy CW，Jessup M，Bozkurt B，et al.American College of Cardiology Foundation；American Heart Association Task Force on Practice Guidelines.2013 ACCF/AHA guideline for the management of heart failure：a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelinees[J].J Am Coll Cardiol，2013，62（16）：e147-e239.
[14]
Shao MJ，Wang SR，Zhao MJ，et al.The effects of velvet antler of deer on cardiac functions of rats with heart failure following myocardial infarction[J].Evid Based Complement Alternat Med，2012，24（4）：7131-7149.
[15]
Chen J，Yao Y，Chen H，et al.Shengmai （a traditional Chinese herbal medicine）for heart failure[J].Cochrane Database Syst Rev，2012，14（11）：CD005052.
[16]
Li X，Zhang J，Huang J，et al.A multicenter，randomized，double-blind，parallel-group，placebo-controlled study of the effects of qili qiangxin capsules in patients with heart failure[J].J Am Coll Cardiol，2013，62（12）：1065-1072.
O′Gara PT，Kushner FG，Ascheim DD，et al.2013ACCF/AHA guideline for the management of ST-elevation myocardial infarction：executive summary：a report of the American College of Cardiology Foundation/American Heart Associatin Task Force on Practice Guidelines[J].Circulation，2013，82（1）：529-555.
[20]
Anderson J，Adams C，Antman E，et al.2012 ACCF/AHA focused update imcorporated into the ACCFAHA 2007 guidelinesforthemanagementofpatientswithunstableangina/nonst-elevation myocardial infarction[J].Circulation，2013，62（11）：1040-1041.
京公网安备 11010502046607号